Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
Thermo Fisher delivered strong Q1 results, beating expectations with revenue of $12.21B (+7% YoY) and EPS of $6.57 (+8%). I reaffirm my strong buy rating on TMO, setting a target price of $668 per share, citing resilient margins and competitive positioning. TMO's 2026 guidance calls for $46.3B-$47.2B revenue (+4-6%) and EPS of $24.22-$24.80 (+6-8%), with organic growth of 4%.
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (TMO) Q4 2025 Earnings Call Transcript
Thermo Fisher stock slides on cautious profit guidance
Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) delivered a fourth quarter earnings beat, but its shares moved lower as investors focused on margin pressures and cautious earnings guidance for 2026. The life sciences tools and diagnostics company guided 2026 revenue to a range of $46.3 billion to $47.2 billion, implying 4% to 6% growth and organic growth of 3% to 4%, broadly in line with consensus expectations and indicating continued modest demand across biopharma and life sciences end markets.
Thermo Fisher (TMO) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher's Q4 Earnings & Revenues Top Estimates, Stock Climbs
TMO beats Q4 EPS and revenue estimates, posts 7.1% sales growth, and sees shares rise after results despite margin pressure.
Thermo Fisher Scientific (TMO) Beats Q4 Earnings and Revenue Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $6.57 per share, beating the Zacks Consensus Estimate of $6.43 per share. This compares to earnings of $6.1 per share a year ago.
Thermo Fisher beats quarterly results estimates on demand for tools from pharma clients
Thermo Fisher Scientific on Thursday beat Wall Street estimates for fourth-quarter profit and revenue on strong demand for its tools and services used in drug development by pharmaceutical clients.
Countdown to Thermo Fisher (TMO) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Thermo Fisher (TMO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings?
TMO heads into Q4 earnings with Specialty Diagnostics growth, fresh FDA approvals and launches that could lift results on Jan. 29.
Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth
Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
TMO ramps up acquisitions and product launches to drive growth, but heavy debt and currency headwinds raise questions for long-term holders.
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
